Study finds Alzheimer’s disease biomarkers in tears
Larger study planned to validate pilot results


Cheryl Guttman Krader
Published: Thursday, May 2, 2019
Results from a pilot trial conducted at Maastricht University, Maastricht, The Netherlands, suggest the possibility of using tear biomarkers as a diagnostic tool for Alzheimer’s disease.
The research was presented by Marlies Gijs, PhD at the annual meeting of the Association for Research in Vision and Ophthalmology in Vancouver, Canada. The study analysed levels of total-tau and amyloid-beta 42 in tear samples collected using Schirmer strips from 34 subjects who represented four subgroups: persons with Alzheimer’s disease, persons with mild cognitive impairment, persons with subjective cognitive impairment, and age-matched healthy controls.
Dr Gijs reported that the concentration of total tau increased with increasing dementia severity and that the concentration of amyloid-beta 42 decreased with increasing disease severity. A Receiver Operating Characteristic curve analysis showed that the discriminatory power of the tear biomarkers for the Alzheimer’s disease state was better than that of the same biomarkers in cerebrospinal fluid.
“We are now planning a larger study with 306 patients to validate these pilot results,” said Dr Gijs.
Tags: Alzheimer's Disease, biomarkers, tear samples
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.